JP2020533408A - 炎症性腸疾患を制御するためのバクテリオファージ - Google Patents

炎症性腸疾患を制御するためのバクテリオファージ Download PDF

Info

Publication number
JP2020533408A
JP2020533408A JP2020535321A JP2020535321A JP2020533408A JP 2020533408 A JP2020533408 A JP 2020533408A JP 2020535321 A JP2020535321 A JP 2020535321A JP 2020535321 A JP2020535321 A JP 2020535321A JP 2020533408 A JP2020533408 A JP 2020533408A
Authority
JP
Japan
Prior art keywords
kp2m
kp2w
kp3w
bacteriophage
bacteriophages
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020535321A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533408A5 (enExample
Inventor
賢也 本田
賢也 本田
幸二 新
幸二 新
聖子 成島
聖子 成島
エリナブ エラン
エリナブ エラン
ソレック ロテム
ソレック ロテム
カブラ エフラット
カブラ エフラット
ベン ダビッド ハヴァ
ベン ダビッド ハヴァ
ウェインストック エヤル
ウェインストック エヤル
ポロック サラ
ポロック サラ
ムティウヒン ユリア
ムティウヒン ユリア
ザック ナオミ
ザック ナオミ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Biomx Ltd
Original Assignee
Yeda Research and Development Co Ltd
Biomx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd, Biomx Ltd filed Critical Yeda Research and Development Co Ltd
Publication of JP2020533408A publication Critical patent/JP2020533408A/ja
Publication of JP2020533408A5 publication Critical patent/JP2020533408A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020535321A 2017-09-08 2018-09-07 炎症性腸疾患を制御するためのバクテリオファージ Withdrawn JP2020533408A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762555790P 2017-09-08 2017-09-08
US62/555,790 2017-09-08
PCT/IB2018/001128 WO2019048930A2 (en) 2017-09-08 2018-09-07 BACTERIOPHAGE OF MODULATION OF INFLAMMATORY INTESTINAL DISEASE

Publications (2)

Publication Number Publication Date
JP2020533408A true JP2020533408A (ja) 2020-11-19
JP2020533408A5 JP2020533408A5 (enExample) 2021-10-07

Family

ID=64316588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020535321A Withdrawn JP2020533408A (ja) 2017-09-08 2018-09-07 炎症性腸疾患を制御するためのバクテリオファージ

Country Status (7)

Country Link
US (1) US20220031776A1 (enExample)
EP (2) EP3678639B1 (enExample)
JP (1) JP2020533408A (enExample)
CN (1) CN111801107A (enExample)
AU (1) AU2018330848A1 (enExample)
CA (1) CA3074406A1 (enExample)
WO (1) WO2019048930A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112469426B (zh) * 2018-05-23 2025-07-11 布莱阿姆青年大学 噬菌体组合物和试剂盒及相关方法
US11986502B2 (en) 2018-05-23 2024-05-21 Optium, LLC Bacteriophage compositions and kits and related methods
CA3131316A1 (en) 2019-03-07 2020-09-10 Keio University Bacteriophage for modulating inflammatory bowel disease
US20240075084A1 (en) * 2021-01-21 2024-03-07 Biomx Ltd. Klebsiella bacteriophage and uses thereof
US20250281553A1 (en) * 2021-04-22 2025-09-11 Ferring B.V. Bacteriophage therapy against adherent-invasive escherichia coli
CN115558650B (zh) * 2022-10-09 2023-05-30 优宜邦生物科技(上海)有限公司 一种宽宿主谱变栖克雷伯氏菌噬菌体及其应用和制剂
CN118318913A (zh) * 2024-05-09 2024-07-12 江苏省农业科学院 一种含有噬菌体的新型饲料添加剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
EP2799063A1 (en) * 2013-04-30 2014-11-05 Ferring B.V. Bacteriophage therapy
CN106754745B (zh) * 2016-11-29 2020-07-14 江苏省农业科学院 一种肺炎克雷伯氏菌噬菌体及其应用

Also Published As

Publication number Publication date
EP3678639B1 (en) 2022-02-16
CA3074406A1 (en) 2019-03-14
AU2018330848A1 (en) 2020-03-12
EP4032526A1 (en) 2022-07-27
WO2019048930A2 (en) 2019-03-14
US20220031776A1 (en) 2022-02-03
CN111801107A (zh) 2020-10-20
EP3678639A2 (en) 2020-07-15
WO2019048930A3 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
US11197897B2 (en) Methods and compositions for reducing vancomycin-resistant enterococci infection or colonization
EP3678639B1 (en) Bacteriophage for modulating inflammatory bowel disease
Kim et al. Lactobacillus plantarum CBT LP3 ameliorates colitis via modulating T cells in mice
CA3026327A1 (en) Methods and compositions for preventing infection by a vibrio species
US12390499B2 (en) Bacteriophage for modulating inflammatory bowel disease
JP2022133363A (ja) Ｔｈ１細胞を誘導する細菌
US12011466B2 (en) Modified Escherichia coli strain Nissle and treatment of gastrointestinal disorder
US20210095327A1 (en) Biomarker and treatment target for alcoholic hepatitis
Zheng et al. Eugenol alleviates Salmonella Typhimurium-infected cecal injury by modulating cecal flora and tight junctions accompanied by suppressing inflammation
CN115666607A (zh) 粪球菌属细菌用于治疗代谢综合征和炎性肠病的用途
US20230181659A1 (en) Phage-mediated delivery of genes to gut microbiome
US20240350563A1 (en) Biotherapeutic enterococcus isolates
Zhang et al. Regulation of Gut Microbiota on
US20200085886A1 (en) Methods and compositions for reducing listeria monocytogenes infection or colonization
CA3217216A1 (en) Bacteriophage therapy against adherent-invasive escherichia coli
Liu Genomic and metagenomic studies of the gut and skin microbiome with probiotic applications

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210830

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20220519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220520